| 1 |
Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients |
|
| | Laura A. Hatfield,Haiden A. Huskamp,Elizabeth B. Lamont | | | Journal of Oncology Practice. 2016; 12(7): 666 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience |
|
| | M.V. Bluthgen,C. Boutros,F. Fayard,J. Remon,D. Planchard,B. Besse | | | Lung Cancer. 2016; 99: 111 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: A large retrospective study |
|
| | Annemiek M. van Maldegem,Charlotte Benson,Piotr Rutkowski,Jean-Yves Blay,Henk van den Berg,Joanna Placzke,Meybrit Rasper,Ian Judson,Heribert Juergens,Uta Dirksen,Hans Gelderblom | | | Pediatric Blood & Cancer. 2014; : n/a | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Carboplatin (renally dosed) and etoposide regimen for small-cell lung cancer |
|
| | Rutledge, M.R. and Waddell, J.A. and Solimando Jr., D.A. | | | Hospital Pharmacy. 2013; 48(4): 274-279 | | | [Pubmed] [Google Scholar] | | | 5 |
Carboplatin (Renally Dosed) and Etoposide Regimen for Small-Cell Lung Cancer |
|
| | Matthew Rutledge,Matthew Waddell,Dominic Solimando, Jr | | | Hospital Pharmacy. 2013; 48(4): 274 | | | [Pubmed] [Google Scholar] [DOI] | |
|
